iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic

Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD’s Breast AI Suite helps her detect the breast cancers radiologists fear most

NASHUA, N.H., July 12, 2023 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr. Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is Finding the Breast Cancers Radiologists Fear the Most,” the live event will take place on Thursday, July 20 at 10 am ET. The event will be moderated by iCAD’s President and CEO, Dana Brown. To register, visit this link.

“iCAD’s Breast AI Suite is revolutionizing breast cancer screening. Our cutting-edge technology not only elevates the skills of the nation’s top radiologists but also reinforces their excellence,” commented Dana Brown, President and CEO of iCAD, Inc. “We look forward to showcasing Dr. Dean in this compelling event, where she will provide valuable insights from her clinical experience, share best practices, and present compelling case studies that highlight the distinctive workflow advantages and unique value our technologies offer to clinicians, facilities, and patients.”

During the event, Dr. Dean will discuss how she leverages iCAD’s market-leading technology to detect breast cancers, including small, subtle tumors – the types of cancers radiologists fear the most. She will also present a live clinical case review showcasing how ProFound AI® can enhance cancer detection in a clinical setting.

“Even for experienced radiologists, some findings are so subtle they can be difficult to detect,” said Dr. Dean. “ProFound AI acts as an extra set of eyes that empowers our team to catch even the smallest, most difficult-to-detect cancers – and with greater accuracy than ever. This reliable, game-changing technology not only improves our confidence, it optimizes efficiency and improves patient outcomes.”

ProFound AI became the first technology of its kind to be FDA cleared in 2018. Built with the latest in deep-learning artificial intelligence, ProFound AI is clinically proven to improve radiologists’ sensitivity by 8%, reduce the rate of false positives and unnecessary callbacks by 7%, and slash reading time by more than half.1

Launched last year, the “ProFound Insights, ProFound Impact” webinar series has featured a number of esteemed clinical, IT, and administrative experts, along with customer success stories and impactful case studies from healthcare facilities around the globe. Previous event recordings are available on the Company’s website, www.icadmed.com.

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.


Media Inquiries:
Jessica Burns, iCAD

Investor Inquiries:
iCAD Investor Relations

1 Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096

error: Content is protected !!